Faculty host:  George Q. Daley, MD, PhD (CHB)

Program abstract:
Cellular reprogramming now allows scientists to establish pluripotent stem cell lines from virtually any patient, promising a range of new approaches to drug discovery and cell replacement therapies.  Scientists from the Harvard Stem Cell Institute will review the advantages and limitations of induced pluripotent stem cells for medical applications in the near term and the long term.

Faculty discussants:
"Similarities and differences between ES cells and iPS cells"
Konrad Hochedlinger, PhD
Massachusetts General Hospital and
Associate Professor, HSCRB / Principal Faculty, HSCI

"Epigenetic dynamics in ES and iPS cells"
Alexander Meissner, PhD
Assistant Professor, HSCRB / Principal Faculty, HSCI
Broad Institute of MIT and Harvard

"ES and iPS based strategies for cell therapy in Parkinson's disease"
Ole Isacson, MD
Professor of Neurology (Neuroscience), Harvard Medical School
Director, Center for Neuroregeneration Research / Neuroregeneration Laboratories, McLean Hospital

"Directing iPS cell differentiation down the motor neuron lineage for cell therapy and disease studies"
Kevin Eggan, PhD
Associate Professor, HSCRB / Principal Faculty, HSCI

Beer/wine and light refreshments will be provided for a post-discussion networking session.

Click here for a flyer to post in your lab.